

## **AMENDMENT TO CLAIMS**

The listing of claims will replace all prior versions and listing of claims in the application:

### **Listing of Claims:**

Claim 1 (cancelled).

Claim 2 (cancelled).

Claim 3 (cancelled).

Claim 4 (canceled).

Claim 5 (cancelled).

Claim 6 (cancelled).

Claim 7 (cancelled).

Claim 8 (cancelled).

Claim 9 (cancelled).

Claim 10 (cancelled).

Claim 11 (previously canceled).





Claim 12 (previously canceled).

Claim 13 (currently amended): A method of treating airway and gastrointestinal disorders inflammation, allergy, nasal congestion, diseases of the GI tract, cardiovascular disease, or disturbances of the central nervous system as well as allergy-induced airway responses, and obesity, said method comprising administering to a mammalian patient in need of such treatment a pharmaceutical composition which comprises therapeutically effective amounts of a compound of claim 4 16.





Claim 14 (previously cancelled).


Claim 15 (currently amended): A method of preparing a pharmaceutical composition for treating airway and gastrointestinal disorders inflammation, allergy, nasal congestion, diseases of the GI tract, cardiovascular disease, or disturbances of the central nervous system as well as allergy-induced airway responses, and obesity, said method comprising bringing into intimate contact a compound of claim 4 16 and a pharmaceutically acceptable carrier.

Claim 16 (previously amended): A compound exhibiting H<sub>3</sub> antagonist activity, or enantiomers, stereoisomers and tautomers of said compound, or pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the compounds with structures listed below:



Claim 17 (previously amended): A compound exhibiting both H<sub>1</sub> and H<sub>3</sub> antagonist activity, or enantiomers, stereoisomers and tautomers of said compound, or pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the compounds with structures listed below:





Claim 18 (currently amended): A pharmaceutical composition for treating airway and gastrointestinal disorders ~~inflammation, allergy, nasal congestion, diseases of the GI tract, cardiovascular disease, or disturbances of the central nervous system as well as allergy induced airway responses, and obesity,~~ said composition comprising therapeutically effective amount of a compound of claim 16 or claim 17 and a pharmaceutically acceptable carrier.

Claims 19-21 (cancelled).

Claim 22 (new claim): A method of treating airway and gastrointestinal disorders, said method comprising administering to a mammalian patient in need of such treatment a pharmaceutical composition which comprises therapeutically effective amounts of a compound of claim 17.

Claim 23 (new claim): A method of preparing a pharmaceutical composition for treating airway and gastrointestinal disorders, said method comprising bringing into intimate contact a compound of claim 17 and a pharmaceutically acceptable carrier.